• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎重症监护病房患者机械通气持续时间影响因素的回顾性队列研究

Retrospective Cohort Study on Determinants of Mechanical Ventilation Duration of COVID-19 ICU Patients.

作者信息

Alsuwat Khalid J, Sonbul Yasseer Y, Alharbi Khalid, Alfaraj Fatimah Baqer, Aljohani Ammar M, Alosaimi Hadeel, Alshehri Abdulmohsen A, Aljarid Manar Y, Alalweni Bara, Alghamdi Kheder, Alqahtani Mansour S, Almadani Noura, Kharaba Ayman M

机构信息

Department of Surgery, College of Medicine, King Hamad University Hospital, Taif, SAU.

Department of Internal Medicine, College of Medicine, King Abdulaziz University, Jeddah, SAU.

出版信息

Cureus. 2024 Jan 29;16(1):e53169. doi: 10.7759/cureus.53169. eCollection 2024 Jan.

DOI:10.7759/cureus.53169
PMID:38420058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10901425/
Abstract

Background In the face of the ongoing global health crisis posed by COVID-19, it becomes imperative to understand the disease's dynamics, particularly in specific regions. This study provides a detailed examination of the factors influencing mechanical ventilation (MV) duration among COVID-19 patients in an intensive care setting, focusing on a diverse patient cohort from the Al Hassa region of Saudi Arabia. The primary aim of this study was to identify key demographic factors, clinical outcomes, and comorbidities that affect the duration of MV among ICU patients with COVID-19. This understanding is crucial for enhancing patient care and informing healthcare strategies in the context of the pandemic. Methods A retrospective cohort study was conducted involving patients diagnosed with COVID-19 and admitted to the ICU in the Al Hassa region. The total number of participants was 1,259. Using a systematic sampling method, these participants were chosen to create a representative sample that reflects the prevailing treatment protocols in ICUs across these hospitals. Data encompassed patient demographics, comorbidities, clinical outcomes, and MV duration. Statistical analyses were employed to explore the associations between these variables. Results Our findings reveal a total of 1,259 participants significant associations between MV duration and various factors, including nationality, legal status, travel history, and comorbidities like heart failure and immunocompromised status. These insights are instrumental in understanding the nuances of COVID-19 management in critical care. Conclusion The study provides valuable insights into the determinants of MV duration in severe COVID-19 cases, emphasizing the need for individualized patient care approaches. It highlights the complexity of managing COVID-19 in ICU settings and underscores the importance of tailored healthcare responses to this global health challenge, particularly in the Al Hassa region.

摘要

背景 面对由新冠病毒 19 型(COVID-19)引发的持续全球健康危机,了解该疾病的动态变化变得至关重要,尤其是在特定地区。本研究详细考察了重症监护环境下影响 COVID-19 患者机械通气(MV)持续时间的因素,重点关注沙特阿拉伯哈萨地区的不同患者群体。本研究的主要目的是确定影响 COVID-19 重症监护病房(ICU)患者 MV 持续时间的关键人口统计学因素、临床结局和合并症。这种理解对于加强患者护理以及在大流行背景下为医疗保健策略提供信息至关重要。方法 进行了一项回顾性队列研究,纳入哈萨地区被诊断为 COVID-19 并入住 ICU 的患者。参与者总数为 1259 人。采用系统抽样方法选择这些参与者,以创建一个反映这些医院 ICU 现行治疗方案的代表性样本。数据包括患者人口统计学、合并症、临床结局和 MV 持续时间。采用统计分析方法探讨这些变量之间的关联。结果 我们的研究结果显示,在 1259 名参与者中,MV 持续时间与多种因素之间存在显著关联,包括国籍、法律身份、旅行史以及心力衰竭和免疫功能低下状态等合并症。这些见解有助于理解重症监护中 COVID-19 管理的细微差别。结论 该研究为重症 COVID-19 病例中 MV 持续时间的决定因素提供了有价值的见解,强调了个性化患者护理方法的必要性。它突出了 ICU 环境中管理 COVID-19 的复杂性,并强调了针对这一全球健康挑战制定量身定制的医疗保健应对措施的重要性,特别是在哈萨地区。

相似文献

1
Retrospective Cohort Study on Determinants of Mechanical Ventilation Duration of COVID-19 ICU Patients.新型冠状病毒肺炎重症监护病房患者机械通气持续时间影响因素的回顾性队列研究
Cureus. 2024 Jan 29;16(1):e53169. doi: 10.7759/cureus.53169. eCollection 2024 Jan.
2
Age and Comorbidity Profiles as Predictors of Mechanical Ventilation Duration in COVID-19 ICU Patients: A Retrospective Study in Saudi Arabia.年龄和合并症情况作为新冠病毒肺炎重症监护病房患者机械通气持续时间的预测因素:沙特阿拉伯的一项回顾性研究
Cureus. 2024 Jan 26;16(1):e52976. doi: 10.7759/cureus.52976. eCollection 2024 Jan.
3
Impact of Corticosteroid Therapy on ICU Patient Outcomes in Severe COVID-19 Cases: A Retrospective Cohort Study in Saudi Arabia.皮质类固醇疗法对重症新型冠状病毒肺炎患者重症监护病房结局的影响:沙特阿拉伯的一项回顾性队列研究
Cureus. 2024 Feb 1;16(2):e53412. doi: 10.7759/cureus.53412. eCollection 2024 Feb.
4
Body Mass Index as a Predictor of COVID-19 Severity in ICU Patients in Saudi Arabia: A Retrospective Analysis.沙特阿拉伯重症监护病房患者中体重指数作为新冠病毒疾病严重程度预测指标的回顾性分析
Cureus. 2024 Jan 17;16(1):e52470. doi: 10.7759/cureus.52470. eCollection 2024 Jan.
5
Impact of Tracheostomy on COVID-19 ICU Patients in Saudi Arabia: A Retrospective Analysis.气管切开术对沙特阿拉伯新冠肺炎重症监护病房患者的影响:一项回顾性分析。
Cureus. 2024 Jan 22;16(1):e52766. doi: 10.7759/cureus.52766. eCollection 2024 Jan.
6
Demographic Characteristics, Comorbidities, and Length of Stay of COVID-19 Patients Admitted Into Intensive Care Units in Saudi Arabia: A Nationwide Retrospective Study.沙特阿拉伯重症监护病房收治的COVID-19患者的人口统计学特征、合并症及住院时间:一项全国性回顾性研究
Front Med (Lausanne). 2022 Jul 13;9:893954. doi: 10.3389/fmed.2022.893954. eCollection 2022.
7
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
8
Impact of Using Antiviral Therapy on COVID-19 Progression in ICU Patients: A Saudi Arabian Retrospective Analysis.抗病毒治疗对ICU中COVID-19患者病情进展的影响:沙特阿拉伯的一项回顾性分析。
Cureus. 2024 Jan 11;16(1):e52096. doi: 10.7759/cureus.52096. eCollection 2024 Jan.
9
The Relationship of ABO and Rh Blood Group Types With Severe COVID-19 Disease Mortality in ICU Patients: Insights From a Single-Center Experience in Southern Saudi Arabia.ABO和Rh血型与ICU患者中重症COVID-19疾病死亡率的关系:来自沙特阿拉伯南部单中心经验的见解
Cureus. 2023 Dec 22;15(12):e50935. doi: 10.7759/cureus.50935. eCollection 2023 Dec.
10
Epidemiological Characteristics and Outcomes Predictors for Intensive Care Unit COVID-19 Patients in Al-Madinah, Saudi Arabia. Retrospective Cohort Study.沙特阿拉伯麦地那重症监护病房新冠肺炎患者的流行病学特征及预后预测因素。回顾性队列研究。
Infect Drug Resist. 2023 Aug 24;16:5573-5586. doi: 10.2147/IDR.S419724. eCollection 2023.

本文引用的文献

1
What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study.在奥密克戎时代,索特罗维单抗在降低 COVID-19 患者疾病进展和死亡方面的疗效如何?一项真实研究的答案。
Viruses. 2023 Aug 17;15(8):1757. doi: 10.3390/v15081757.
2
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.莫努匹韦、奈玛特韦/利托那韦或索托维单抗用于感染奥密克戎变异株的高危COVID-19患者:现实生活中的住院率、死亡率及核酸检测转阴时间
Pharmaceuticals (Basel). 2023 May 9;16(5):721. doi: 10.3390/ph16050721.
3
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.在真实世界环境中探索使用单克隆抗体和抗病毒疗法对 COVID-19 门诊患者进行早期治疗:来自英国和意大利的全国性研究。
BioDrugs. 2023 Sep;37(5):675-684. doi: 10.1007/s40259-023-00601-w. Epub 2023 May 6.
4
Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression.早期 SARS-CoV-2 抗病毒治疗对疾病进展的影响。
Viruses. 2022 Dec 27;15(1):71. doi: 10.3390/v15010071.
5
COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients.欧盟批准的 COVID-19 治疗方法和非住院及住院患者管理的临床建议。
Ann Med. 2022 Dec;54(1):2856-2860. doi: 10.1080/07853890.2022.2133162.
6
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.奥密克戎变异株流行期间香港社区居住、活动的经实验室确诊的 2 型严重急性呼吸综合征冠状病毒 2 感染患者中莫努匹韦和奈玛特韦/利托那韦对比死亡率、住院率和住院结局的真实世界疗效:一项观察性研究。
Lancet. 2022 Oct 8;400(10359):1213-1222. doi: 10.1016/S0140-6736(22)01586-0.
7
Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.治疗用单克隆抗体和直接抗病毒药物后,SARS-CoV-2 BA.1 和 BA.2 奥密克戎亚谱系感染的病毒载量下降。
J Med Virol. 2023 Jan;95(1):e28186. doi: 10.1002/jmv.28186. Epub 2022 Oct 7.
8
Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.奥密克戎 BA.2 波期间香港住院的 COVID-19 患者无入院时吸氧需求的患者中早期莫努匹韦或奈玛特韦-利托那韦的真实世界疗效:一项回顾性队列研究。
Lancet Infect Dis. 2022 Dec;22(12):1681-1693. doi: 10.1016/S1473-3099(22)00507-2. Epub 2022 Aug 24.
9
Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.瑞德西韦早期给药与 COVID-19 患者的更高康复率和更低的 ICU 入院需求相关:一项回顾性队列研究。
PLoS One. 2021 Oct 26;16(10):e0258643. doi: 10.1371/journal.pone.0258643. eCollection 2021.
10
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.